Connection
Jeffrey Montgomery to Urinary Bladder Neoplasms
This is a "connection" page, showing publications Jeffrey Montgomery has written about Urinary Bladder Neoplasms.
|
|
Connection Strength |
|
![](https://uams-triprofiles.uams.edu/profiles/Framework/Images/connection_left.gif) |
|
![](https://uams-triprofiles.uams.edu/profiles/Framework/Images/connection_right.gif) |
|
10.081 |
|
|
|
-
Zhu A, Berends JE, Daignault-Newton S, Kaye DR, Parker C, IglayReger H, Morgan TM, Weizer AZ, Kaffenberger SD, Herrel LA, Hafez K, Skolarus TA, Montgomery JS. Use of a physical activity monitor to track perioperative activity of radical cystectomy patients. Our first glimpse at what our patients are doing before and after surgery. Urol Oncol. 2023 04; 41(4):206.e11-206.e19.
Score: 0.767
-
Kaye DR, Schafer C, Thelen-Perry S, Parker C, Iglay-Reger H, Daignault-Newton S, Qin Y, Morgan TM, Weizer AZ, Kaffenberger SD, Herrel LA, Hafez KS, Lee CT, Skolarus TA, Englesbe MJ, Montgomery JS. The Feasibility and Impact of a Presurgical Exercise Intervention Program (Prehabilitation) for Patients Undergoing Cystectomy for Bladder Cancer. Urology. 2020 11; 145:106-112.
Score: 0.642
-
Li AY, Filson CP, Hollingsworth JM, He C, Weizer AZ, Hollenbeck BK, Gilbert SM, Hafez KS, Lee CT, Dunn RL, Montgomery JS. Patient-Reported Convalescence and Quality of Life Recovery: A Comparison of Open and Robotic-Assisted Radical Cystectomy. Surg Innov. 2016 Dec; 23(6):598-605.
Score: 0.484
-
Montgomery JS. Editorial comment for Sim et al. J Endourol. 2015 Apr; 29(4):390.
Score: 0.434
-
Montgomery JS, Miller DC, Weizer AZ. Quality indicators in the management of bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):492-500.
Score: 0.386
-
Montgomery JS, Weizer AZ, Montie JE. Editorial comment. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology. 2011 Mar; 77(3):667-8.
Score: 0.334
-
Weizer AZ, Tallman C, Montgomery JS. Long-term outcomes of intravesical therapy for non-muscle invasive bladder cancer. World J Urol. 2011 Feb; 29(1):59-71.
Score: 0.328
-
Weizer AZ, Palella GV, Montgomery JS. Managing muscle-invasive bladder cancer in the elderly. Expert Rev Anticancer Ther. 2010 Jun; 10(6):903-15.
Score: 0.317
-
Montgomery JS, Weizer AZ, Montie JE. T1 bladder cancer: advocating early cystectomy to improve oncologic control. Urol Oncol. 2010 Sep-Oct; 28(5):466-8.
Score: 0.316
-
Merrill NM, Kaffenberger SD, Bao L, Vandecan N, Goo L, Apfel A, Cheng X, Qin Z, Liu CJ, Bankhead A, Wang Y, Kathawate V, Tudrick L, Serhan HA, Farah Z, Ellimoottil C, Hafez KS, Herrel LA, Montgomery JS, Morgan TM, Salami SS, Weizer AZ, Ulintz PJ, Day ML, Soellner MB, Palmbos PL, Merajver SD, Udager AM. Integrative Drug Screening and Multiomic Characterization of Patient-derived Bladder Cancer Organoids Reveal Novel Molecular Correlates of Gemcitabine Response. Eur Urol. 2024 Nov; 86(5):434-444.
Score: 0.213
-
Sekar RR, Irani S, Maganty A, Montgomery JS, Herrel LA. Social Vulnerability and Receipt of Neoadjuvant Chemotherapy in Patients Undergoing Radical Cystectomy for Bladder Cancer. Urology. 2024 Sep; 191:79-84.
Score: 0.209
-
Narayan VM, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Inman BA, Williams MB, Cookson MS, Chang SS, Sankin AI, O'Donnell MA, Sawutz D, Philipson R, Parker NR, Yla-Herttuala S, Rehm D, Jakobsen JS, Juul K, Dinney CPN. Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Gu?rin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial. J Urol. 2024 Jul; 212(1):74-86.
Score: 0.208
-
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Buyyounouski MK, Chan K, Chang SS, Chang P, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kaimakliotis H, Kishan AU, Kundu S, Lele SM, Mamtani R, Mian OY, Michalski J, Montgomery JS, Parikh M, Patterson A, Peyton C, Plimack ER, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Stewart T, Sundi D, Tollefson M, Tward J, Wright JL, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 05; 22(4):216-225.
Score: 0.208
-
Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21.
Score: 0.203
-
Kirk PS, Lotan Y, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Spiess PE, van Rhijn BWG, Mertens L, Black P, Wright JL. Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort. J Urol. 2023 05; 209(5):882-889.
Score: 0.192
-
Einerhand SMH, Black AJ, Zargar H, Fairey AS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobson NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Garcia JA, Stephenson AJ, Shah JB, Daneshmand S, Zargar-Shoshtari K, Spiess PE, van Rhijn BWG, Black PC, Mertens LS. Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer. World J Urol. 2022 Nov; 40(11):2707-2715.
Score: 0.186
-
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. NCCN Guidelines? Insights: Bladder Cancer, Version 2.2022. J Natl Compr Canc Netw. 2022 08; 20(8):866-878.
Score: 0.184
-
Mitra AP, Narayan VM, Mokkapati S, Miest T, Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown GA, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Philipson R, Yl?-Herttuala S, Sawutz D, Parker NR, McConkey DJ, Dinney CPN. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.177
-
D'Andrea D, Black PC, Zargar H, Dinney CP, Soria F, Cookson MS, Montgomery JS, Kassouf W, Dall'Era MA, Sridhar SS, McGrath JS, Wright JL, Thorpe AC, Holzbeierlein JM, Carri?n DM, Di Trapani E, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer. J Urol. 2022 01; 207(1):70-76.
Score: 0.173
-
D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Soria F, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer. World J Urol. 2021 Dec; 39(12):4345-4354.
Score: 0.172
-
Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM, Bivalacqua TJ, Montgomery JS, Lerner SP, Busby JE, Poch M, Crispen PL, Steinberg GD, Schuckman AK, Downs TM, Svatek RS, Mashni J, Lane BR, Guzzo TJ, Bratslavsky G, Karsh LI, Woods ME, Brown G, Canter D, Luchey A, Lotan Y, Krupski T, Inman BA, Williams MB, Cookson MS, Keegan KA, Andriole GL, Sankin AI, Boyd A, O'Donnell MA, Sawutz D, Philipson R, Coll R, Narayan VM, Treasure FP, Yla-Herttuala S, Parker NR, Dinney CPN. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.164
-
Corona LE, Singhal U, Hafez K, Herrel LA, Kaffenberger SD, Montgomery JS, Morgan TM, Weizer AZ, Qin Y, Ambani SN. Rethinking the one-size-fits-most approach to venous thromboembolism prophylaxis after radical cystectomy. Urol Oncol. 2020 10; 38(10):797.e1-797.e6.
Score: 0.160
-
Lee MS, Shen M, Williams A, Kendrick D, Weizer A, Montgomery J. Retroureteral Small Bowel Herniation Resulting in Bowel Obstruction Following Robotic Cystectomy With Extracorporeal Ileal Conduit. Urology. 2021 01; 147:3-6.
Score: 0.160
-
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 03; 18(3):329-354.
Score: 0.156
-
D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF. Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer. Urol Oncol. 2020 07; 38(7):639.e1-639.e9.
Score: 0.155
-
Kirk PS, Liu X, Borza T, Li BY, Sessine M, Zhu K, Lesse O, Qin Y, Jacobs B, Urish K, Helm J, Gilbert S, Weizer A, Montgomery J, Hollenbeck BK, Lavieri M, Skolarus TA. Dynamic readmission prediction using routine postoperative laboratory results after radical cystectomy. Urol Oncol. 2020 04; 38(4):255-261.
Score: 0.155
-
Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC. The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy. Urol Oncol. 2020 01; 38(1):3.e17-3.e27.
Score: 0.152
-
Venkatramani V, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Soodana-Prakash N, Becerra MF, Swain S, Kendrick K, Smith JA, Thompson IM, Parekh DJ. Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup. J Urol. 2020 03; 203(3):522-529.
Score: 0.151
-
Mannan R, Taylor AS, Spratt DE, Chinnaiyan AM, Montgomery JS, Brown NA, Mehra R. TERT- beyond the territory: Usage of PCR-based TERT promoter assay in defining urothelial carcinoma in a case of long-standing prostatic adenocarcinoma. Pathol Res Pract. 2020 Jan; 216(1):152663.
Score: 0.151
-
Modi PK, Hollenbeck BK, Oerline M, Weizer AZ, Montgomery JS, Kaffenberger SD, Ryan AM, Ellimoottil C. Real-World Impact of Minimally Invasive Versus Open Radical Cystectomy on Perioperative Outcomes and Spending. Urology. 2019 03; 125:86-91.
Score: 0.142
-
Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 09; 16(9):1041-1053.
Score: 0.141
-
Hovelson DH, Udager AM, McDaniel AS, Grivas P, Palmbos P, Tamura S, Lazo de la Vega L, Palapattu G, Veeneman B, El-Sawy L, Sadis SE, Morgan TM, Montgomery JS, Weizer AZ, Day KC, Neamati N, Liebert M, Keller ET, Day ML, Mehra R, Tomlins SA. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. Eur Urol. 2018 12; 74(6):741-753.
Score: 0.139
-
Udager AM, McDaniel AS, Hovelson DH, Fields K, Salami SS, Kaffenberger SD, Spratt DE, Montgomery JS, Weizer AZ, Reichert ZR, Alva AS, Chinnaiyan AM, Tomlins SA, Mehra R. Frequent PD-L1 Protein Expression and Molecular Correlates in Urinary Bladder Squamous Cell Carcinoma. Eur Urol. 2018 10; 74(4):529-531.
Score: 0.139
-
Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, Weizer AZ, Konety BR, Tollefson M, Krupski TL, Smith ND, Shabsigh A, Barocas DA, Quek ML, Dash A, Kibel AS, Shemanski L, Pruthi RS, Montgomery JS, Weight CJ, Sharp DS, Chang SS, Cookson MS, Gupta GN, Gorbonos A, Uchio EM, Skinner E, Venkatramani V, Soodana-Prakash N, Kendrick K, Smith JA, Thompson IM. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet. 2018 06 23; 391(10139):2525-2536.
Score: 0.139
-
Brown NA, Lew M, Weigelin HC, Weizer AZ, Montgomery JS, Betz BL, Mehra R. Comparative study of TERT promoter mutation status within spatially, temporally and morphologically distinct components of urothelial carcinoma. Histopathology. 2018 01; 72(2):354-356.
Score: 0.132
-
Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267.
Score: 0.132
-
Osawa T, Ambani SN, Olugbade K, Skolarus TA, Weizer AZ, Montgomery JS, He C, Hafez KS, Hollenbeck BK, Lee CT, Montie JE, Palapattu GS, Morgan TM. Potential Implications of Shortening Length of Stay Following Radical Cystectomy in a Pre-ERAS Population. Urology. 2017 04; 102:92-99.
Score: 0.125
-
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.
Score: 0.123
-
Krishnan N, Li B, Jacobs BL, Ambani SN, Borza T, He C, Hollenbeck BK, Morgan T, Hafez KS, Weizer AZ, Montgomery JS, Lee CT, Lesse O, Lavieri MS, Helm JE, Skolarus TA. The Fate of Radical Cystectomy Patients after Hospital Discharge: Understanding the Black Box of the Pre-readmission Interval. Eur Urol Focus. 2018 09; 4(5):711-717.
Score: 0.122
-
Anderson C, Weber R, Patel D, Lowrance W, Mellis A, Cookson M, Lang M, Barocas D, Chang S, Newberger E, Montgomery JS, Weizer AZ, Lee CT, Kava BR, Jackson M, Meraney A, Sjoberg D, Bochner B, Dalbagni G, Donat M, Herr H. A 10-Item Checklist Improves Reporting of Critical Procedural Elements during Transurethral Resection of Bladder Tumor. J Urol. 2016 Oct; 196(4):1014-20.
Score: 0.119
-
Smith ND, Castle EP, Gonzalgo ML, Svatek RS, Weizer AZ, Montgomery JS, Pruthi RS, Woods ME, Tollefson MK, Konety BR, Shabsigh A, Krupski T, Barocas DA, Dash A, Quek ML, Kibel AS, Parekh DJ. The RAZOR (randomized open vs robotic cystectomy) trial: study design and trial update. BJU Int. 2015 Feb; 115(2):198-205.
Score: 0.110
-
Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9.
Score: 0.107
-
Jacobs BL, Daignault S, Lee CT, Hafez KS, Montgomery JS, Montie JE, Humrich JE, Hollenbeck BK, Wood DP, Weizer AZ. Prostate capsule sparing versus nerve sparing radical cystectomy for bladder cancer: results of a randomized, controlled trial. J Urol. 2015 Jan; 193(1):64-70.
Score: 0.106
-
McDaniel AS, Zhai Y, Cho KR, Dhanasekaran SM, Montgomery JS, Palapattu G, Siddiqui J, Morgan T, Alva A, Weizer A, Lee CT, Chinnaiyan AM, Quist MJ, Grasso CS, Tomlins SA, Mehra R. HRAS mutations are frequent in inverted urothelial neoplasms. Hum Pathol. 2014 Sep; 45(9):1957-65.
Score: 0.105
-
Hu M, Jacobs BL, Montgomery JS, He C, Ye J, Zhang Y, Brathwaite J, Morgan TM, Hafez KS, Weizer AZ, Gilbert SM, Lee CT, Lavieri MS, Helm JE, Hollenbeck BK, Skolarus TA. Sharpening the focus on causes and timing of readmission after radical cystectomy for bladder cancer. Cancer. 2014 May 01; 120(9):1409-16.
Score: 0.102
-
Filson CP, Montgomery JS, Dailey SM, Crossley HS, Lentz H, Tallman CT, He C, Weizer AZ. Complications associated with single-dose, perioperative mitomycin-C for patients undergoing bladder tumor resection. Urol Oncol. 2014 Jan; 32(1):40.e1-8.
Score: 0.098
-
Grivas PD, Hussain M, Hafez K, Daignault-Newton S, Wood D, Lee CT, Weizer A, Montie JE, Hollenbeck B, Montgomery JS, Alva A, Smith DC. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology. 2013 Jul; 82(1):111-7.
Score: 0.097
-
Shah RB, Montgomery JS, Montie JE, Kunju LP. Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: impact of mandatory central pathology review at a large referral hospital. Urol Oncol. 2013 Nov; 31(8):1650-5.
Score: 0.091
-
Jacobs BL, Montgomery JS, Zhang Y, Skolarus TA, Weizer AZ, Hollenbeck BK. Disparities in bladder cancer. Urol Oncol. 2012 Jan-Feb; 30(1):81-8.
Score: 0.088
-
Skolarus TA, Ye Z, Montgomery JS, Weizer AZ, Hafez KS, Lee CT, Miller DC, Wood DP, Montie JE, Hollenbeck BK. Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology. 2011 Dec; 78(6):1345-9.
Score: 0.087
-
Wolf JS, Dash A, Hollenbeck BK, Johnston WK, Madii R, Montgomery JS. Intermediate followup of hand assisted laparoscopic nephroureterectomy for urothelial carcinoma: factors associated with outcomes. J Urol. 2005 Apr; 173(4):1102-7.
Score: 0.055
-
Stangl-Kremser J, Ahmadi H, Derstine B, Wang SC, Englesbe MJ, Daignault-Newton S, Chernin AS, Montgomery JS, Palapattu GS, Lee CT. Psoas Muscle Mass can Predict Postsurgical Outcomes in Patients Who Undergo Radical Cystectomy and Urinary Diversion Reconstruction. Urology. 2021 12; 158:142-149.
Score: 0.043
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|